RWP
VRTX icon

Revolve Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Revolve Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-498
Closed -$201K – 243
2024
Q4 		$201K Sell
498
-289
-37% -$134K 0.03% 217
2024
Q3 		$366K Sell
787
-11
-1% -$5.28K 0.06% 137
2024
Q2 		$374K Sell
798
-2
-0.3% -$868 0.06% 119
2024
Q1 		$334K Buy
800
+26
+3% +$11K 0.06% 123
2023
Q4 		$315K Buy
774
+17
+2% +$6.28K 0.06% 119
2023
Q3 		$263K Sell
757
-2
-0.3% -$699 0.06% 124
2023
Q2 		$267K Buy
759
+39
+5% +$13.1K 0.06% 115
2023
Q1 		$227K Buy
720
+1
+0.1% +$300 0.06% 129
2022
Q4 		$208K Buy
719
+27
+4% +$8.23K 0.06% 136
2022
Q3 		$200K Sell
692
-57
-8% -$16.4K 0.07% 125
2022
Q2 		$211K Buy
+749
New +$200K 0.07% 128

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Revolve Wealth Partners's VRTX Position: Q1 2025 in Review

Revolve Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 498 shares — an estimated $201K sold.

Revolve Wealth Partners first reported a position in VRTX in Q2 2022 and held it in 11 quarters. The position peaked at $374K in Q2 2024. 1,616 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Revolve Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Revolve Wealth Partners sold 498 Vertex Pharmaceuticals shares in Q1 2025, an estimated $201K.
  • Revolve Wealth Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Revolve Wealth Partners's Vertex Pharmaceuticals position peaked at $374K in Q2 2024.
  • 1,616 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Revolve Wealth Partners's 13F filing for Q1 2025, filed 14 Apr 2025.